Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy

Area of Science:

• Pathology
• Oncology
• Breast Cancer Research

Background:

• Neoadjuvant systemic therapy is increasingly used for breast cancer before surgery.
• Evaluation of post-neoadjuvant breast cancer specimens lacks a universal reporting protocol.
• Current staging systems face challenges in assessing residual tumor burden accurately.

Purpose of the Study:

• To offer guidance for evaluating and reporting post-neoadjuvant breast specimens.
• To discuss limitations of existing staging and reporting systems.
• To propose modifications for the American Joint Committee on Cancer staging and Residual Cancer Burden calculator.

Main Methods:

• Literature review of English-language publications.
• Analysis of data from the I-SPY 2 neoadjuvant clinical trial.

Main Results:

• Identified challenges in the pathologic evaluation of treated breast carcinomas.
• Highlighted the need for standardized reporting protocols.
• Emphasized the utility of the Residual Cancer Burden system for quantifying treatment response.

Conclusions:

• Pathologic evaluation of post-neoadjuvant breast cancer specimens requires clear guidelines.
• Recommendations are provided for pathologists and clinicians.
• Future modifications to staging systems are suggested to improve residual tumor burden assessment.